IL7 and neoplasm: The use of tumor-selective oncolytic vaccinia viruses encoding interleukin-7 (IL-7) and interleukin-12 (IL-12) can make mice with complete tumor regression resist the re-attack by the same tumor cells (Nakao et al., 2020).